These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 29427042)

  • 1. Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System.
    Golomb BA; Verden A; Messner AK; Koslik HJ; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):403-413. PubMed ID: 29427042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
    Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
    Edwards IR; Star K; Kiuru A
    Drug Saf; 2007; 30(6):515-25. PubMed ID: 17536877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
    Fujimoto M; Hosomi K; Takada M
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
    Xiao M; Li L; Zhu W; Wu F; Wu B
    Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of statins on blood pressure: Analysis on adverse events released by FDA.
    You T; Liu XG; Hou XD; Wang XK; Xie HH; Ding F; Yi K; Zhang P; Xie XD
    Clin Exp Hypertens; 2017; 39(4):325-329. PubMed ID: 28513233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.
    Golomb BA; Kwon EK; Koperski S; Evans MA
    Drug Saf; 2009; 32(8):649-61. PubMed ID: 19591530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.
    Gaimari A; Fusaroli M; Raschi E; Baldin E; Vignatelli L; Nonino F; De Ponti F; Mandrioli J; Poluzzi E
    Drug Saf; 2022 Jun; 45(6):663-673. PubMed ID: 35610460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
    Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cataracts and statins. A disproportionality analysis using data from VigiBase.
    Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R
    Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis.
    Chuma M; Nakamoto A; Bando T; Niimura T; Kondo Y; Hamano H; Okada N; Asada M; Zamami Y; Takechi K; Goda M; Miyata K; Yagi K; Yoshioka T; Izawa-Ishizawa Y; Yanagawa H; Tasaki Y; Ishizawa K
    Clin Infect Dis; 2022 Oct; 75(8):1416-1422. PubMed ID: 35262686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins and amyotrophic lateral sclerosis--the level of evidence for an association.
    Sørensen HT; Lash TL
    J Intern Med; 2009 Dec; 266(6):520-6. PubMed ID: 19930099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs.
    Akimoto H; Negishi A; Oshima S; Okita M; Numajiri S; Inoue N; Ohshima S; Kobayashi D
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00439. PubMed ID: 30443347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.
    Sakaeda T; Kadoyama K; Okuno Y
    PLoS One; 2011; 6(12):e28124. PubMed ID: 22205938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between statins and the risk of amyotrophic lateral sclerosis: A PRISMA-compliant meta-analysis.
    Chang MC; Kwak SG; Park JS; Park D
    Medicine (Baltimore); 2021 Jul; 100(30):e26751. PubMed ID: 34397718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
    Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M
    Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database.
    Fujimoto M; Higuchi T; Hosomi K; Takada M
    Int J Med Sci; 2015; 12(3):223-33. PubMed ID: 25678839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.